Received: 19 October 2020 | Accepted: 12 April 2021

DOI: 10.1111/jth.15345

ORIGINAL ARTICLE

FGL1 as a modulator of plasma D-dimer levels: Exome-wide marker analysis of plasma tPA, PAI-1, and D-dimer

Florian Thibord[1] | Ci Song[1] | Jack Pattee[2] | Benjamin A.T. Rodriguez[1] | Ming-Huei Chen[1] | Christopher J. O'Donnell[1,3] | Marcus E. Kleber[4,5] | Graciela E. Delgado[4] | Xiuqing Guo[6] | Jie Yao[6] | Kent D. Taylor[6] | Ayse Bilge Ozel[7] | Jennifer A. Brody[8] | Barbara McKnight[9] | Beata Gyorgy[10] | Eleanor Simonsick[11] | Hampton L. Leonard[11] | Germán D. Carrasquilla[12] | Marta Guindo-Martinez[12] | Angela Silveira[13] | Gerard Temprano-Sagrera[14] | Lisa R. Yanek[15] | Diane M. Becker[15] | Rasika A. Mathias[15,16] | Lewis C. Becker[15,17] | Laura M. Raffield[18] | Tuomas O. Kilpeläinen[12] | Niels Grarup[12] | Oluf Pedersen[12] | Torben Hansen[12] | Allan Linneberg[19] | Anders Hamsten[13] | Hugh Watkins[20] | Maria Sabater-Lleal[13,14] | Mike A. Nalls[11] | David-Alexandre Trégouët[10,21] | Pierre-Emmanuel Morange[22] | Bruce M. Psaty[8] | Russel P. Tracy[23] | Nicholas L. Smith[8,24,25,26] | Karl C. Desch[27] | Mary Cushman[23] | Jerome I. Rotter[6] | Paul S. de Vries[28] | Nathan D. Pankratz[29] | Aaron R. Folsom[30] | Alanna C. Morrison[28] | Winfried März[4,31] | Weihong Tang[30] | Andrew D. Johnson[1]

[1]The Framingham Heart Study, National Heart Lung and Blood Institute, Framingham, Massachusetts, USA

[2]Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA

[3]U.S. Department of Veterans Affairs, Boston, Massachusetts, USA

[4]Vth Department of Medicine, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany

[5]SYNLAB MVZ Humangenetik Mannheim GmbH, Mannheim, Germany

[6]Department of Pediatrics, The Institute for Translational Genomics and Population Sciences, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, USA

[7]Department of Human Genetics, University of Michigan, Ann Arbor, Michigan, USA

[8]Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, and Health Services, University of Washington, Seattle, Washington, USA

[9]Department of Biostatistics, University of Washington, Seattle, Washington, USA

[10]INSERM UMRS1166, ICAN - Institute of CardioMetabolism and Nutrition, Sorbonne Université, Paris, France

[11]National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA

[12]Faculty of Health and Medical Sciences, Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark

[13]Cardiovascular Medicine Unit, Department of Medicine Solna, Karolinska Institutet, Center for Molecular Medicine and Karolinska University Hospital Solna, Stockholm, Sweden

[14]Genomics of Complex Diseases, Research Institute of Hospital de la Santa Creu i Sant Pau, IIB Sant Pau, Barcelona, Spain

[15]GeneSTAR Research Program, Division of General Internal Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA

[16]Division of Allergy and Clinical Immunology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA

Manuscript handled by: Ton Lisman

Final decision: Ton Lisman, 12 April 2021

© 2021 International Society on Thrombosis and Haemostasis. This article has been contributed to by US Government employees and their work is in the public domain in the USA.

[17]Division of Cardiology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA

[18]Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

[19]Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark

[20]Radcliffe Department of Medicine, University of Oxford, Oxford, UK

[21]INSERM, BPH, Univ. Bordeaux, Bordeaux, France

[22]INSERM, INRAE, Aix-Marseille Univ, Marseille, France

[23]Department of Pathology and Laboratory Medicine & Department of Medicine, Vermont Center on Cardiovascular and Brain Health, Larner College of Medicine at the University of Vermont, Burlington, Vermont, USA

[24]Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, Washington, USA

[25]Department of Epidemiology, University of Washington, Seattle, Washington, USA

[26]Department of Veterans Affairs Office of Research and Development, Seattle Epidemiologic Research and Information Center, Seattle,, Washington, USA

[27]Department of Pediatrics, Cell and Molecular Biology Program, University of Michigan, Ann Arbor, Michigan, USA

[28]Human Genetics Center, Department of Epidemiology, Human Genetics, and Environmental Sciences, School of Public Health, The University of Texas Health Science Center at Houston, Houston, Texas, USA

[29]Department of Laboratory Medicine and Pathology, School of Medicine, University of Minnesota, Minneapolis, Minnesota, USA

[30]Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA

[31]Synlab Academy, Synlab Holding Deutschland GmbH, Mannheim, Germany

Correspondence
Andrew D. Johnson, NHLBI Population Sciences Branch, The Framingham Heart Study, 73 Mt. Wayte Ave., Suite #2, Framingham, MA 01702, USA.
Email: johnsonad2@nhlbi.nih.gov

Funding information
Danish Research Councils; Health Foundation in Denmark; Danish Centre for Evaluation and Health Technology Assessment; Copenhagen County; Danish Heart Foundation; Ministry of Health and Prevention in Denmark; Association of Danish Pharmacies; Augustinus Foundation; Novo Nordisk; Velux Foundation; Becket Foundation; Ib Henriksens Foundation; National Heart, Lung, and Blood Institute contracts, Grant/Award Number: NO1-HL 25195 and HHSN268201500001I; NHLBI Intramural funds; MESA, Grant/Award Number: 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-000040, UL1-TR-001079 and UL1-TR-001420; National Center for Advancing Translational Sciences, Grant/Award Number: UL1TR001881; National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC), Grant/Award Number: DK063491; NHLBI, Grant/Award Number: HHSN268201200036C, HHSN268200800007C, HHSN268201800001C, N01HC55222, N01HC85079, N01HC85080, N01HC8508, N01HC85082, N01HC85083 and N01HC85086; NHLBI, Grant/Award Number: U01HL080295, R01HL068986, R01HL087652, R01HL105756, R01HL103612, R01HL120393 and U01HL130114; National Institute of Neurological Disorders and Stroke (NINDS); National Institute on Aging (NIA), Grant/Award Number: R01AG023629; National Center for Advancing Translational Sciences, Grant/Award Number: UL1TR001881; National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC), Grant/Award Number: DK063491; National Heart, Lung, and Blood Institute; National Institutes of Health; Department of Health and Human Services, Grant/Award Number: HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I and HHSN268201700005I; NIH, Grant/Award Number: 5RC2HL102419; 6th Framework Program of the European Union, Grant/Award Number: LSH-2005-2.1.1-1; ISCIII Spanish Health Institute, Grant/Award Number: CP17/00142; European Social Fund; Foundation for Strategic Research, Grant/Award Number: 8691; Swedish Heart-Lung Foundation, Grant/Award Number: 12660; Swedish Research Council, Grant/Award Number: 20653; European Commission, Grant/Award Number: LSHM-CT-2007-037273; Knut and Alice Wallenberg Foundation; Torsten and Ragnar Söderberg Foundation; Strategic Cardiovascular and Diabetes Programmes of Karolinska Institutet; Stockholm County Council; Stockholm County Council, Grant/Award Number: 560183; GENMED Laboratory of Excellence on Medical Genomics, Grant/Award Number: ANR-10-LABX-0013; National Institutes of Health/National Heart, Lung, and Blood Institute, Grant/Award Number: HL59684 and HL112064; Johns Hopkins University School of Medicine General Clinical Research Center; National Institutes of Health, Grant/Award Number: M01 RR00052; U.S.; federal government, Grant/Award Number: HHSN268201100037C; National Institutes of Health/National Heart, Lung, and Blood Institute, Grant/Award Number: HL135793 and HL141399; CHARGE Hemostasis Working Group, Grant/Award Number: HL134894 and HL139553; NHLBI, Grant/Award Number: N02-HL-64278 and UCLA CTSI UL1-TR001881; S. Calif, Grant/Award Number: DRC DK063491; Novo Nordisk Foundation, Grant/Award Number: NNF17SA0031406, NNF18CC0034900, NNF17OC0026848, NNF15CC0018486 and NNF18CC0034900; American Heart Association, Grant/Award Number: 18CDA34110116

Abstract

Background: Use of targeted exome-arrays with common, rare variants and functionally enriched variation has led to discovery of new genes contributing to population variation in risk factors. Plasminogen activator-inhibitor 1 (PAI-1), tissue plasminogen activator (tPA), and the plasma product D-dimer are important components of the fibrinolytic system. There have been few large-scale genome-wide or exome-wide studies of PAI-1, tPA, and D-dimer.

Objectives: We sought to discover new genetic loci contributing to variation in these traits using an exome-array approach.
Methods: Cohort-level analyses and fixed effects meta-analyses of PAI-1 (n = 15 603), tPA (n = 6876,) and D-dimer (n = 19 306) from 12 cohorts of European ancestry with diverse study design were conducted, including single-variant analyses and gene-based burden testing.
Results: Five variants located in *NME7*, *FGL1*, and the fibrinogen locus, all associated with D-dimer levels, achieved genome-wide significance ($P < 5 \times 10^{-8}$). Replication was sought for these 5 variants, as well as 45 well-imputed variants with $P < 1 \times 10^{-4}$ in the discovery using an independent cohort. Replication was observed for three out of the five significant associations, including a novel and uncommon (0.013 allele frequency) coding variant p.Trp256Leu in *FGL1* (fibrinogen-like-1) with increased plasma D-dimer levels. Additionally, a candidate-gene approach revealed a suggestive association for a coding variant (rs143202684-C) in *SERPINB2*, and suggestive associations with consistent effect in the replication analysis include an intronic variant (rs11057830-A) in *SCARB1* associated with increased D-dimer levels.
Conclusion: This work provides new evidence for a role of *FGL1* in hemostasis.

KEYWORDS
computational biology, exome, fibrinogen, fibrinolysis, genetic association study

1 | INTRODUCTION

The use of targeted gene arrays with rare variants and functionally enhanced variation has led to the discovery of new genetic loci contributing to population variation in risk factors including lipids; blood pressure; and hematology traits including platelet, red cell and white cell measurements, clotting factors, and platelet aggregation.[1-6] Fibrin D-dimer, tissue plasminogen activator (tPA), and plasminogen activator-inhibitor 1 (PAI-1) are important biomarkers and regulators of hemostasis. Plasma PAI-1 degrades tPA, as well as urinary plasminogen activator, and inhibits the conversion of plasminogen to plasmin, thus inhibiting downstream fibrinolysis. Levels and activity of PAI-1 are causally linked to risk of coronary artery disease (CAD), as demonstrated by Mendelian randomization analysis.[7] Due to its ability to potently activate fibrinolysis, tPA is an effective treatment when administered soon after stroke events.[8] As the major byproduct of fibrinolysis, plasma D-dimer level reflects fibrin formation and reactive fibrinolysis. Higher D-dimer is a risk factor for venous thromboembolism (VTE), stroke, and CAD.[9]

Given their importance as biomarkers and regulators of clot formation and degradation, deciphering the genetic architecture of these traits may have clinical relevance and may help improve our understanding of fibrinolytic and clotting mechanisms. However, there are few large-scale, population-based, genome-wide or exome-wide studies of plasma levels of PAI-1, tPA, and D-dimer. These previous works identified 1p21.3 (upstream of *F3*), 1q24.2 (encompassing *F5* and *NME7*), and 4q32.1 (fibrinogen locus, between *FGG* and *FGA*) associated with D-dimer levels;[10] 7q22.1 (*SERPINE1* promoter and near *MUC3A*) and 11p15.3 (within *ARNTL*) associated with PAI-1 levels;[11] and 6q24.3 (within *STXBP5*), 8p11.21 (*POLB-PLAT* locus), and 12q24.33 (within *STX2*) associated with tPA levels.[12] Here, we leveraged an exome-wide variant array designed to capture an enriched portion of functional and rare variation to find new genetic determinants of PAI-1, tPA, and D-dimer.

Essentials

- D-dimer, plasminogen activator-inhibitor 1 (PAI-1), and tissue plasminogen activator (tPA) levels are important biomarkers and regulators of hemostasis.
- We performed an exome-wide association study of these three traits in up to 19,300 individuals.
- A novel *FGL1* variant was associated with D-dimer and replicated in an independent cohort.
- Our study provides new evidence for a role of FGL1 in hemostasis.

2 | METHODS

This project derives from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium hemostasis working group and involves participants from 12 cohorts of European ancestry (ARIC, CHS, FHS, GABC, GeneSTAR, HABC, Inter99, LURIC, MARTHA, MESA, PROCARDIS, and SCARF).[13] Plasma levels (ng/mL or IU/mL) of D-dimer were measured in 7 studies (N = 19 306), tPA in 7 studies (N = 6876), and PAI-1 in 11 studies (N = 15 603). Participants using anticoagulant therapy at the time of phlebotomy were excluded. A description of each cohort is given in Table S1 and Methods S1 in supporting information. All studies were approved by their respective institutional review board and participants provided informed consent.

Genotypes were assayed using the Illumina HumanExome BeadChip v1.0 or v1.2 (Illumina, Inc.) in accordance with the manufacturer's instructions. Single nucleotide polymorphism (SNP) calling and quality control procedures were conducted by each study following a common protocol, which has been described previously.[1,14]

Each study performed statistical analyses independently following a common protocol. Phenotype measurements were log transformed and analyses were adjusted for age, sex, principal components (PCs) derived from genotypes, and study-design variables. PCs were selected for adjustment if they were significantly associated with the trait analyzed in an age- and sex-adjusted model. Sex-stratified analyses were also performed for all cohorts except Inter99, and adjusted for age, PCs, and study-specific variables. Both single SNP and multiple SNP (gene-level) association analyses were conducted with the seqMeta R library (https://github.com/DavisBrian/seqMeta). The results of individual studies were combined using an inverse variance weighted fixed-effect meta-analysis with seqMeta. Conditional analyses were conducted with GCTA-COJO,[15] and linkage disequilibrium estimation was performed with PLINK[16] in the FHS cohort.

For the single SNP analysis, only variants with a minimal allele count greater than five across cohorts were interrogated. A total of 101,541 SNPs were considered for association with D-dimer levels, 95,138 SNPs with PAI-1 levels, and 68,725 SNPs with tPA levels. We used both an agnostic and candidate-gene approach involving genes related to the coagulation pathway referenced by the KEGG pathway hsa04610 (Table S2 in supporting information). For the agnostic approach, the threshold for significance was set using the Bonferroni method at $P < 1.88 \times 10^{-7}$ (0.05/265,404). A replication step to validate the results was performed in the Caerphilly Prospective Study (CaPS),[17] composed of European males, with genotypes imputed using the HRC 1.1 dataset.[18] Both significant and suggestive ($P < 1 \times 10^{-4}$) associations from the discovery meta-analysis were tested in CaPS with a one-sided hypothesis, with a threshold for significance at nominal P-value (.05).

However, single variants tests lack power to identify associations of rare variants, which constitute a large part of the Exome chip. To assess the effect of these rare variants, we performed gene-based tests, which allow for each gene to test the joint effect of rare variants contained in each gene. Two distinct methods were applied: Sequence Kernel Association Test (SKAT)[19] and the classical burden test.[20] For both tests, the joint effect of variants with minimal allele frequency (MAF) < 0.05 were considered. Only genes with >1 SNP were tested. For each trait, about 15,000 genes were considered for these analyses, and the threshold for significance was set at $P < 1.09 \times 10^{-6}$ (0.05/45 833).

Results from all single-variant and gene-based analyses are publicly available on the GRASP portal (https://grasp.nhlbi.nih.gov/FullResults.aspx).

3 | RESULTS

3.1 | Single variant analyses

Manhattan and quantile-quantile (Q-Q) plots representing the results of the discovery meta-analysis of single-SNP associations are provided for D-dimer (Figure S1-S2 in supporting information), PAI-1 (Figure S3-S4 in supporting information), and tPA (Figure S5-S6 in supporting information). No single variant exceeded the threshold of genome-wide significance for tPA or PAI-1 plasma levels. The single-SNP analysis of D-dimer revealed five genome-wide significant associations at three distinct regions: *FGL1*, *NME7* and the fibrinogen coding loci (encompassing *FGG*, *FGA*, and *FGB*) (Table 1). At the *FGL1* locus, two missense variants rs2653414-A (p. Trp256Leu, MAF = 0.013, β = 0.21, $P = 3.93 \times 10^{-11}$) and rs3739406-T (p. Ile72Val, MAF = 0.32, β = 0.05, $P = 3.71 \times 10^{-9}$) were associated with higher D-dimer levels. The two *FGL1* variants were in partial linkage disequilibrium (r^2 = 0.02; D' = 1.0), but after conditioning the analysis on rs2653414, the association of rs3739406 with D-dimer levels remained high ($P = 9.40 \times 10^{-7}$), implying independent associations. The phenotypic variance explained by rs2653414 and rs3739406 is 0.23% and 0.18%, respectively. The associations observed at *NME7* (rs16861990-C, MAF = 0.070, β = 0.12, $P = 1.17 \times 10^{-11}$) and upstream of *FGA* (rs13109457-A, MAF = 0.25, β = 0.05, $P = 1.24 \times 10^{-7}$) were previously described in a genome-wide association study (GWAS) of plasma D-dimer levels,[10] while the *FGG* missense variant (rs148685782-C, p. Ala108Gly, MAF = 0.004, β = −0.38, $P = 6.75 \times 10^{-11}$) was previously associated with fibrinogen level.[21]

We then sought to replicate the significant associations from the discovery meta-analysis in CaPS. The results from the replication analysis are presented in Table 1. We observed a replication for three out of the five significant associations with D-dimer levels, one at each locus: rs16861990 (β = 0.13, p = .001) in *NME7*, rs2653414 (β = 0.23, p = .04) in *FGL1*, and rs13109457 (β = 0.07, p = .001) at the fibrinogen locus, upstream of *FGA*. Additionally, we investigated all suggestive associations ($P < 1 \times 10^{-4}$) with D-dimer, tPA, or PAI-1 levels from the discovery analysis in CaPS. Of the 79 variants suggestively associated in the discovery, 45 were available in CaPS. We observed directionally consistent results for three associations, one with tPA levels and a missense variant in *MTFR1L* (rs201393961, p. Thr83Met), and two with D-dimer levels: an intronic *SCARB1* variant

TABLE 1 Results of the discovery and replication analyses

				Discovery (meta-analysis)					Replication (CaPS)				
Chr:Position	dbSNPID	Gene	EA/NEA	MAF	*N*	β	SE	*P*[a]	MAF	β	SE	*P*[b]	RSQ
D-dimer									(*N* = 1112)				
1:169135127	rs16861990	*NME 7*(intronic)	C/A	0.070	15733	0.119	0.018	1.17E−11	0.061	0.135	0.044	0.0010	0.98
8:17726069	rs2653414	*FGL1* (p. Trp256Leu)	A/C	0.013	19306	0.213	0.032	3.93E−11	0.006	0.233	0.133	0.0404	0.97
4:155533035	rs148685782	*FGG* (p. Ala108Gly)	C/G	0.004	19306	−0.384	0.059	6.75E−11	0.001	−0.112	0.386	0.3854	0.48
8:17739538	rs3739406	*FGL1* (p. Ile72Val)	T/C	0.325	19306	0.047	0.008	3.71E−09	0.291	0.003	0.023	0.4467	1.00
4:155514879	rs13109457	3 kb 5' of *FGA* (intergenic)	A/G	0.249	18607	0.047	0.009	1.24E−07	0.246	0.072	0.024	0.0012	1.00
4:155542248	rs7681423	8.3 kb 5' of *FGG* (intergenic)	T/C	0.238	18607	0.045	0.009	5.58E−07	0.228	0.072	0.024	0.0013	0.99*
12:125307053	rs11057830	*SCARB1* (intronic)	A/G	0.158	15733	0.058	0.012	3.62E−06	0.146	0.071	0.030	0.0087	0.98*
tPA									(*N* = 1111)				
1:26153114	rs201393961	*MTFR1L* (p. Thr83Met)	T/C	0.001	3346	0.676	0.162	3.11E−05	0.001	0.536	0.260	0.0196	0.68*

Abbreviations: CaPS, Caerphilly Prospective Study; EA, effect allele; MAF, minor allele frequency; NEA, non-effect allele; RSQ, imputation quality; SE, standard error.

[a]In the discovery meta-analysis, the threshold for significant associations was set using the Bonferroni method to 1.88×10^{-7}.

[b]In the replication analysis, associations below the nominal *P*-value were deemed significant under a one-sided hypothesis.

*Suggestive associations from the discovery with same effect direction in CaPS and $P < .05$.

(rs11057830), and rs7681423 upstream of *FGG* (Table 1). These variants all had high imputation quality (RSQ >0.9), except for the *MTFR1L* variant, which had moderate quality (RSQ = 0.68).

All significant and suggestive associations from the discovery analysis as well as the results of the replication analysis are provided in Table S3 in supporting information. As D-dimer levels can be related to thrombotic events, we also inspected the association of the novel replicated variant (*FGL1* rs2653414) and other novel variants of interest (*FGL1* rs3739406, *SCARB1* rs11057830) with VTE risk in the INVENT GWAS dataset,[22] but none of these variants were found to be associated (Table S4 in supporting information).

3.2 | Single variant analyses restricted to candidate genes

We also applied a candidate gene approach to retrieve associations implicating genes involved in the coagulation pathway (as listed in Table S2) that did not meet the exome-wide single SNP significance threshold. This approach revealed two missense variants suggestively associated with D-dimer: rs201909029-C (p. Lys178Asn, MAF = 0.007, $\beta = -0.72$, $P = 1.25 \times 10^{-6}$) located in *FGB* at the fibrinogen locus, not previously associated with D-dimer or fibrinogen, and rs143202684-C (p. Gly218Ala, MAF = 0.001, $\beta = -0.41$, $P = 8.10 \times 10^{-5}$) located in *SERPINB2*, which encodes the PAI-2 protein. The poor imputation quality of these two rare variants (RSQ < 0.1) prevented our effort to investigate these suggestive associations further in CaPS.

3.3 | Gene-based burden analyses

The gene-based analysis revealed two genes significantly associated with plasma D-dimer: *FGL1* and *FGG*. The results of these two associations were similar for both SKAT and T5 methods, and were mainly driven by the variants associated with D-dimer in the single-SNP analysis (the details of single variant associations involved in both *FGL1* and *FGG* gene-based tests are given in Table S5 in supporting information). For each method and for each trait analyzed, the results of the three most significant gene-based associations are presented in Table 2, while the results of all associations with $P < .0001$ are provided in Table S6 in supporting information.

3.4 | Sex-stratified analyses

As previous studies have reported that genetic associations with hemostatic factors can differ between males and females, we conducted sex-stratified analyses of the three traits.[23] The single variant analyses yielded two significant associations: one between D-dimer levels in women and the *FGG* variant rs148685782, previously identified in the main analysis, and one between tPA levels in women and a rare missense variant in *KIAA1432* (rs143886234-G, p. Pro443Arg, MAF = 0.001, minor allele count [MAC] = 6, $\beta = 1.53$, $P = 3.14 \times 10^{-8}$). However, with a total of only six minor alleles supporting this signal, in three out of the six studies with sex-stratified D-dimer results, it could be a false positive. Unfortunately, we were unable to verify this signal in an independent cohort, as our only replication dataset was CaPS, which is only composed of men. We also retrieved the sex-specific effects for all associations identified in the main analyses. The associations at *NME7/F5 region*, *FGG*, *FGL1*, *FGA*, *SCARB1*, and *SERPINB2* all reached at least nominal significance in both sexes, and no significant difference in effect was observed between sex. The association at *FGB* did not reach nominal significance in men, most likely because of its rare frequency. The details of these associations are available in Table S7 in supporting information.

Gene-based sex-specific analyses also revealed a novel gene, *ENOX2*, associated with D-dimer levels in men, according to the results of the SKAT analysis (Table S8 in supporting information). However, after further inspection of the *ENOX2* variants, only two variants with MAF < 0.05 were considered for this test (Table S9 in supporting information), and the gene-based association with D-dimer levels in men was driven by only one of them: rs200194256 (MAF = 0.0001, MAC = 2, $P = 1.19 \times 10^{-7}$).

3.5 | FGL1 investigation

As FGL1 possesses a fibrinogen C-terminus domain, we investigated its similarity with the fibrinogen subunits proteins. We observed that the FGL1 C-terminus domain is homologous to the fibrinogen gamma subunit (46% according to Clustal2.1), and the variant whose D-dimer association was replicated in CaPS (rs2653414) is located in a codon encoding a tryptophan amino acid conserved in the fibrinogen subunit (Figure S7 in supporting information). The rs2653414 variant has not been previously associated with any phenotype or transcript levels (see annotations in Table S3). However, it was recently found to be associated with decreased levels of the FGL1 protein in serum ($\beta = -1.62$, $P = 4.22 \times 10^{-47}$).[24]

4 | DISCUSSION

In order to discover new functional and rare genetic determinants of plasma tPA, PAI-1, and D-dimer levels, we performed both single- and multi-variant meta-analyses using exome-wide marker genotype data from 12 cohorts. For D-dimer, we identified three associations previously observed in genome-wide studies of D-dimer levels or fibrinogen,[10,21] and two novel associations of variants in *FGL1*, of which one was replicated in CaPS. The analyses of tPA and PAI-1 levels did not reveal any exome-chip--wide significant associations, and overall the sex-stratified analyses did not yield strong evidence supporting different genetic effects in men and women at most of the loci we observed.

TABLE 2 Most significant results from the gene-based analyses for plasma PAI-1, tPA and D-dimer levels

T5 (MAF < 0.05)						SKAT (MAF < 0.05)			
Gene	*p*	β	SE	Cmaf	N_{snp}	Gene	*p*	Cmaf	N_{snp}
PAI−1 (*N* = 15 063)									
STAT3	9.65E−05	−1.63	0.42	0.0001	3	*STAT3*	5.82E−06	0.0001	3
AKAP11	1.07E−04	−0.08	0.02	0.0451	44	*USP38*	9.89E−06	0.0010	8
KIF1B	3.40E−04	−0.06	0.02	0.0763	24	*GPN3*	2.99E−05	0.0021	3
tPA (*N* = 6876)									
SH2D6	3.15E−06	−0.73	0.16	0.0009	4	*STX2*	2.96E−05	0.0271	7
CRCP	2.49E−05	−0.49	0.12	0.0011	3	*SH2D6*	3.17E−05	0.0009	4
SGCG	2.91E−05	−0.39	0.09	0.0025	7	*ZBTB41*	4.01E−05	0.0062	9
D-dimer (*N* = 19 306)									
FGG	3.75E−08	−0.19	0.03	0.0120	9	*FGG*	4.47E−09	0.0120	9
FGL1	2.60E−07	0.05	0.01	0.0910	17	*FGL1*	2.86E−08	0.0910	17
EIF2AK3	2.02E−06	−0.22	0.05	0.0069	9	*EIF2AK3*	5.98E−06	0.0069	9

Abbreviations: Cmaf, Cumulative MAF; N_{snp}, Number of SNPs used in the gene-based test; SE, Standard Error.

FGL1, which encodes the fibrinogen-like 1 protein, is expressed mainly in the liver and can be found circulating in plasma. It has been linked to various biological processes including mitogenic activity in hepatocytes promoting liver growth,[25] acute phase reactant upregulated by IL6 during inflammation,[26] and more recently immunity.[27] A role in coagulation has previously been hypothesized because of its similarity with FGG and FGB C-terminal domains,[28] but was mainly rejected because of its lack of sites necessary for fibrin clot formation. However, subsequent studies reported FGL1 to bind fibrin clots in plasma,[29,30] although it is not known how this occurs. The replicated *FGL1* variant (rs2653414) associated with higher levels of D-dimer has been recently found associated with lower serum levels of the FGL1 protein in an exome-chip analysis of protein levels,[24] but there is no evidence that transcript levels of FGL1 levels are affected according to eQTL resources such as GTeX (Table S3). This discrepancy could be first explained by an impact of the variant on the protein structure, which could either affect the stability of the protein and reduce its levels, or it could alter the epitope of the protein and affect its detection by the proteomic assay. Additionally, because most eQTL resources are based on GWAS arrays they may lack appropriate coverage for this variant. This conclusion seems consistent with the fact that prior large GWAS studies of D-dimer did not discover an association with *FGL1*. Furthermore, an association of an *FGL1* variant with D-dimer levels was previously observed in an exome study of a Finnish population,[31] in which an uncommon insertion causing a frameshift in *FGL1* (rs201941547, p. Asn182 fs, MAF = 0.037, $\beta = 0.21$, $P = 6.12 \times 10^{-6}$) was associated with higher D-dimer, but the authors were unable to replicate their results due to a lack of D-dimer phenotype in their replication sample. This frameshift variant most likely implicates a loss of function of FGL1, and the similar increase of D-dimer levels observed in our analysis for a missense variant strongly tied to lower circulating FGL1 levels suggests that impaired FGL1 levels or function may generally result in higher D-dimer. Therefore, while the specific role of this protein in the coagulation process is unclear, the associations of *FGL1* missense variants identified in our study together with the results from the Finnish study[31] provide strong evidence for the implication of this gene in the modulation of D-dimer levels.

Additionally, we observed two suggestive associations with D-dimer which could be of interest if further validated. First, a rare *SERPINB2* missense variant (p. Gly218Ala) was associated with lower D-dimer. However, similar to FGL1, the role of PAI-2 in the coagulation process is not clearly established. Early investigations showed that PAI-2 could act as an inhibitor of urokinase plasminogen activator (uPA) *in vitro* and it was found associated to fibrin clots.[32] More recently a study reported that deep venous thrombosis models of mice lacking *Serpinb2* had increased uPA activity and enhanced venous thrombosis resolution.[33] Second, an intronic *SCARB1* variant was associated with higher D-dimer, which was replicated in CaPS. This gene encodes a scavenger receptor protein of class B, which mediates cholesterol transfer in and out of lipoproteins. This variant was previously associated with risk of CAD,[34] a condition often having a component of altered fibrinolytic function. Interestingly, *Scarb1*$^{-/-}$ mice had increased risk of venous thrombosis.[35] Furthermore, expressing endothelial Scarb1 protected mice against atherosclerosis, and in an *ApoE4*$^{-/-}$ background decreased aortic lesion size ~24% at 8 months, suggesting roles in lipid metabolism and other biological functions at the level of vessel walls where fibrinolysis also occurs.[36]

Previous genetic analyses of D-dimer, PAI-1, and tPA were conducted on a genome-wide scale using imputed datasets. The use of exome chip data in the present study permitted us to confirm some of these previous findings, and more importantly, it allowed us to focus on new associations involving less common variants that are often absent or poorly imputed in GWAS datasets. However, this also impaired our ability to replicate several associations in CaPS, such as the rare *SERPINB2* variant, and it will be of future interest to replicate these associations in new exome chip or sequencing studies. Furthermore, we observed inter-cohort variability in measurements,

due in part to the specificity of each population studied, and also as a result of the different assays used to measure plasma levels of D-dimer, PAI-1, and tPA by each study. This could reduce our power to detect genetic associations. However, to reduce this variability, measurements were log-transformed, and we systematically verified that the direction of effect for all significant and suggestive associations were concordant across cohorts, which substantiate the validity of these associations. Finally, our study and findings are also limited at this time to European ancestry populations, so it remains to be seen if these loci are observed in other populations.

In conclusion, we were able to replicate a significant association implicating the locus *FGL1* in the modulation of D-dimer levels, and we discovered two suggestive associations of interest at the *SERPINB2* and *SCARB1* loci. Most notably, these results provide additional evidence for a role of *SERPINB2* and *FGL1* in the coagulation system, two genes previously suspected to play a role in hemostasis.

ACKNOWLEDGMENTS

The Inter99 study was funded by the Danish Research Councils, the Health Foundation in Denmark, Danish Centre for Evaluation and Health Technology Assessment, Copenhagen County, Danish Heart Foundation, Ministry of Health and Prevention in Denmark, Association of Danish Pharmacies, Augustinus Foundation, Novo Nordisk, Velux Foundation, Becket Foundation, and Ib Henriksens Foundation. The Framingham Heart Study was supported by the National Heart, Lung, and Blood Institute contracts NO1-HL 25195 and HHSN268201500001I. Florian Thibord and Andrew Johnson were supported by NHLBI Intramural funds. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the U.S. Department of Health and Human Services. MESA and the MESA SHARe project are conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. Support for MESA is provided by contracts 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-000040, UL1-TR-001079, UL1-TR-001420. The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR001881, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center.

Cardiovascular Health Study: This CHS research was supported by NHLBI contracts HHSN268201200036C, HHSN268200800007C, HHSN268201800001C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086; and NHLBI grants U01HL080295, R01HL068986, R01HL087652, R01HL105756, R01HL103612, R01HL120393, and U01HL130114 with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided through R01AG023629 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR001881, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center. The Atherosclerosis Risk in Communities study (ARIC) has been funded in whole or in part with federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services (contract numbers HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I, and HHSN268201700005I). The authors thank the staff and participants of the ARIC study for their important contributions. Funding support for "Building on GWAS for NHLBI-diseases: the U.S. CHARGE consortium" was provided by the NIH through the American Recovery and Reinvestment Act of 2009 (ARRA) (5RC2HL102419). The Precocious Coronary Artery DISease (PROCARDIS) study project was funded with 10 million Euros through the 6th Framework Program of the European Union (LSH-2005-2.1.1-1). It started in April 2007 and funding lasted until September 2011. After the funding ended, PROCARDIS is still actively doing research in the field of coronary artery disease genetics. Maria Sabater-Lleal is supported by a *Miguel Servet* contract from the ISCIII Spanish Health Institute (CP17/00142) and co-financed by the European Social Fund. Stockholm Coronary Artery Risk Factors (SCARF): The authors would like to thank all participants in this study. The study was funded by the Foundation for Strategic Research, the Swedish Heart-Lung Foundation, the Swedish Research Council (8691, 12660, 20653), the European Commission (LSHM-CT-2007-037273), the Knut and Alice Wallenberg Foundation, the Torsten and Ragnar Söderberg Foundation, the Strategic Cardiovascular and Diabetes Programmes of Karolinska Institutet and the Stockholm County Council, and the Stockholm County Council (560183). MARTHA genetic investigations were financially supported by the GENMED Laboratory of Excellence on Medical Genomics (ANR-10-LABX-0013). GENESTAR: This research was supported by grants HL59684 and HL112064 from the National Institutes of Health/National Heart, Lung, and Blood Institute, Bethesda, Maryland, and the Johns Hopkins University School of Medicine General Clinical Research Center, National Institutes of Health grant M01 RR00052. Genotyping services were provided through the RS&G Service by the Northwest Genomics Center at the University of Washington, Department of Genome Sciences, under U.S. federal government contract number HHSN268201100037C from the National Heart, Lung, and Blood Institute. The Genes and Blood Clotting Study is supported by funds from HL135793 and HL141399 from the National Institutes of Health/National Heart, Lung, and Blood Institute, Bethesda,

Maryland. The CHARGE Hemostasis Working Group is supported by funds from HL134894 and HL139553. Provision of exome chip genotyping was provided in part by support of NHLBI contract N02-HL-64278 and UCLA CTSI UL1-TR001881, and the S. Calif DRC DK063491. DAT was supported by the «EPIDEMIOM-VTE» Senior Chair from the Initiative of Excellence of the University of Bordeaux. Germán D. Carrasquilla was supported by the Danish Diabetes Academy, which is funded by the Novo Nordisk Foundation, grant number NNF17SA0031406. Tuomas O. Kilpeläinen was supported by the Novo Nordisk Foundation (NNF18CC0034900, NNF17OC0026848, NNF15CC0018486). Novo Nordisk Foundation Center for Basic Metabolic Research is an independent research center, based at the University of Copenhagen, Denmark, and partially funded by an unconditional donation from the Novo Nordisk Foundation (www.cbmr.ku.dk; grant number NNF18CC0034900). Paul S. de Vries was supported by American Heart Association grant number 18CDA34110116.

CONFLICTS OF INTEREST

The authors have no conflicts of interest.

AUTHOR CONTRIBUTIONS

For each study, data were produced by M.-H. Chen, C.J. O'Donnell, and A.D. Johnson for FHS; J. Pattee, N.D. Pankratz, W. Tang, A. Folsom, P.S. DeVries, and A.C. Morrison for ARIC; J.A. Brody, B. McKnight, B.M. Psaty, R.P. Tracy, and N.L Smith for CHS; M.E. Kleber, G.E. Delgado, and W. Marz for LURIC; B. Gyorgy, D.-A. Tregouet, and P.-E. Morange for MARTHA; A.B. Ozel and K. Desch for GABC; X. Guo, J. Yao, K.D. Taylor, M. Cushman, and J.I. Rotter for MESA; H. Leonard, E. Simonsick, and M.A. Nalls for HABC; G.D. Carrasquilla, M. Guindo-Martinez, T.O. Kilpeläinen, N. Grarup, O. Pedersen, T. Hansen, and A. Linneberg for Inter99; A. Silveira, G. Temprano-Sagrera, A. Hamsten, H. Watkins, and M. Sabater-Lleal for SCARF and PROCARDIS; L.R. Yanek, D.M. Becker, R.A. Mathias, and L.C. Becker for GENESTAR. L.M. Raffield helped with replicating associations. The statistical analyses were performed by F. Thibord, C. Song, and B.A.T Rodriguez under the direction of A.D. Johnson. F. Thibord and A.D. Johnson drafted the manuscript. All authors provided critical feedback and helped shape the research, analysis, and manuscript.

ORCID

Florian Thibord https://orcid.org/0000-0003-2229-8322
Nicholas L. Smith https://orcid.org/0000-0003-3483-353X
Mary Cushman https://orcid.org/0000-0002-7871-6143
Aaron R. Folsom https://orcid.org/0000-0003-2635-2699
Weihong Tang https://orcid.org/0000-0003-1200-0270
Andrew D. Johnson https://orcid.org/0000-0001-6369-5178

REFERENCES

1. Peloso GM, Auer PL, Bis JC, et al. Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks. *Am J Hum Genet*. 2014;94:223-232.
2. Eicher JD, Chami N, Kacprowski T, et al. Platelet-related variants identified by exomechip meta-analysis in 157,293 individuals. *Am J Hum Genet*. 2016;99:40-55.
3. Pankratz N, Schick UM, Zhou Y, et al. Meta-analysis of rare and common exome chip variants identifies S1PR4 and other loci influencing blood cell traits. *Nat Genet*. 2016;48:867-876.
4. Chami N, Chen M-H, Slater AJ, et al. Exome genotyping identifies pleiotropic variants associated with red blood cell traits. *Am J Hum Genet*. 2016;99:8-21.
5. Huffman JE, de Vries PS, Morrison AC, et al. Rare and low-frequency variants and their association with plasma levels of fibrinogen, FVII, FVIII, and vWF. *Blood*. 2015;126:e19-29.
6. Chen M-H, Yanek LR, Backman JD, et al. Exome-chip meta-analysis identifies association between variation in ANKRD26 and platelet aggregation. *Platelets*. 2019;30:164-173.
7. Song C, Burgess S, Eicher JD, O'Donnell CJ, Johnson AD. Causal effect of plasminogen activator inhibitor type 1 on coronary heart disease. *J Am Heart Assoc*. 2017;6.
8. Wardlaw JM, Murray V, Berge E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. *Lancet*. 2012;379:2364-2372.
9. Wolberg AS, Rosendaal FR, Weitz JI, et al. Venous thrombosis. *Nat Review Dis Primers*. 2015;1:1-17.
10. Smith NL, Huffman JE, Strachan DP, et al. Genetic predictors of fibrin D-dimer levels in healthy adults. *Circulation*. 2011;123:1864-1872.
11. Huang J, Sabater-Lleal M, Asselbergs FW, et al. Genome-wide association study for circulating levels of PAI-1 provides novel insights into its regulation. *Blood Am Soc Hematol*. 2012;120:4873-4881.
12. Huang J, Huffman JE, Yamakuchi M, et al. Genome-wide association study for circulating tissue plasminogen activator levels and functional follow-up implicates endothelial STXBP5 and STX2. *Arterioscler Thromb Vasc Biol*. 2014;34:1093-1101.
13. Psaty BM, O'Donnell CJ, Gudnason V, et al., CHARGE Consortium. Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: Design of prospective meta-analyses of genome-wide association studies from 5 cohorts. *Circ Cardiovasc Genet*. 2009;2:73-80.
14. Grove ML, Yu B, Cochran BJ, et al. Best practices and joint calling of the HumanExome BeadChip: the CHARGE Consortium. *PLoS One*. 2013;8:e68095.
15. Yang J, Ferreira T, Morris AP, et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nat Gene*. 2012;44:369-375.
16. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet*. 2007;81:559-575.
17. Rodriguez BAT, Bhan A, Beswick A, et al. A platelet function modulator of thrombin activation is causally linked to cardiovascular disease and affects PAR4 receptor signaling. *Am J Human Gene Elsevier*. 2020;107(2):211-221.
18. McCarthy S, Das S, Kretzschmar W, et al. A reference panel of 64,976 haplotypes for genotype imputation. *Nat Genet*. 2016;48:1279-1283.
19. Wu MC, Lee S, Cai T, Li Y, Boehnke M, Lin X. Rare-variant association testing for sequencing data with the sequence kernel association test. *Am J Hum Genet*. 2011;89:82-93.
20. Li B, Leal SM. Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data. *Am J Hum Genet*. 2008;83:311-321.
21. de Vries PS, Chasman DI, Sabater-Lleal M, et al. A meta-analysis of 120 246 individuals identifies 18 new loci for fibrinogen concentration. *Hum Mol Genet*. 2016;25:358-370.
22. Lindstrom S, Wang L, Smith EN, et al. Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism. *Blood*. 2019;134(19):1645-1657.

23. Raffield LM, Zakai NA, Duan Q, et al. D-Dimer in African Americans: whole genome sequence analysis and relationship to cardiovascular disease risk in the jackson heart study. *Arterioscler Thromb Vasc Biol*. 2017;37:2220-2227.
24. Emilsson V, Gudmundsdottir V, Ilkov M, et al. Human serum proteome profoundly overlaps with genetic signatures of disease. *bioRxiv Cold Spring Harbor Laboratory*. 2020;2020:80440.
25. Hara H, Uchida S, Yoshimura H, et al. Isolation and characterization of a novel liver-specific gene, hepassocin, upregulated during liver regeneration. *Biochim Biophys Acta*. 2000;1492:31-44.
26. Liu Z, Ukomadu C. Fibrinogen-like protein 1, a hepatocyte derived protein is an acute phase reactant. *Biochem Biophys Res Commun*. 2008;365:729-734.
27. Wang J, Sanmamed MF, Datar I, et al. Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3. *Cell*. 2019;176(334–347):e12.
28. Yamamoto T, Gotoh M, Sasaki H, Terada M, Kitajima M, Hirohashi S. Molecular cloning and initial characterization of a novel fibrinogen-related gene, HFREP-1. *Biochem Biophys Res Commun*. 1993;193:681-687.
29. Rijken DC, Dirkx SPG, Luider TM, Leebeek FWG. Hepatocyte-derived fibrinogen-related protein-1 is associated with the fibrin matrix of a plasma clot. *Biochem Biophys Res Commun*. 2006;350:191-194.
30. Talens S, Leebeek FWG, Demmers JAA, Rijken DC. Identification of fibrin clot-bound plasma proteins. *PLoS One*. 2012;7:e41966.
31. Lim ET, Würtz P, Havulinna AS, et al. Distribution and medical impact of loss-of-function variants in the Finnish founder population. *PLoS Genet*. 2014;10:e1004494.
32. Ritchie H, Robbie LA, Kinghorn S, Exley R, Booth NA. Monocyte plasminogen activator inhibitor 2 (PAI-2) inhibits u-PA-mediated fibrin clot lysis and is cross-linked to fibrin. *Thromb Haemost*. 1999;81:96-103.
33. Siefert SA, Chabasse C, Mukhopadhyay S, et al. Enhanced venous thrombus resolution in plasminogen activator inhibitor type-2 deficient mice. *J Thromb Haemost*. 2014;12:1706-1716.
34. van der Harst P, Verweij N. Identification of 64 novel genetic loci provides an expanded view on the genetic architecture of coronary artery disease. *Circ Res*. 2018;122:433-443.
35. Brill A, Yesilaltay A, De Meyer SF, et al. Extrahepatic high-density lipoprotein receptor SR-BI and apoA-I protect against deep vein thrombosis in mice. *Arterioscler Thromb Vasc Biol*. 2012;32:1841-1847.
36. Vaisman BL, Vishnyakova TG, Freeman LA, et al. Endothelial expression of scavenger receptor class B, Type I protects against development of atherosclerosis in mice. *Biomed Res Int*. 2015;2015:607120.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Thibord F, Song C, Pattee J, et al. FGL1 as a modulator of plasma D-dimer levels: Exome-wide marker analysis of plasma tPA, PAI-1, and D-dimer. *J Thromb Haemost*. 2021;19:2019–2028. https://doi.org/10.1111/jth.15345